S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)

Novo Nordisk A/S (NVO) News Today

$96.63
-0.18 (-0.19%)
(As of 12/8/2023 ET)
Compare
Today's Range
$96.22
▼
$97.05
50-Day Range
$87.75
▼
$105.35
52-Week Range
$64.44
▼
$105.69
Volume
3.60 million shs
Average Volume
3.43 million shs
Market Capitalization
$433.63 billion
P/E Ratio
40.10
Dividend Yield
0.64%
Price Target
$83.50
Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media
SourceHeadline
finance.yahoo.com logoCould Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?
finance.yahoo.com - December 8 at 10:18 AM
finance.yahoo.com logoPfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?
finance.yahoo.com - December 8 at 10:18 AM
finance.yahoo.com logoSanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus
finance.yahoo.com - December 7 at 5:30 PM
finance.yahoo.com logoPharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal
finance.yahoo.com - December 7 at 5:30 PM
finance.yahoo.com logoAbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B
finance.yahoo.com - December 7 at 7:29 AM
wsj.com logoInside Novo Nordisk, the Danish Drugmaker Behind Ozempic
wsj.com - December 6 at 8:39 PM
benzinga.com logoObesity Drugs: Greater Weight Loss Linked to Prolonged Use of Novo Nordisk's Wegovy
benzinga.com - December 6 at 10:38 AM
marketbeat.com logoSimply Good Foods: Winner in the Ozempic Weight-Loss Trend (NVO)
marketbeat.com - December 6 at 7:32 AM
finance.yahoo.com logoAlterity (ATHE) Up on Preclinical Parkinson's Treatment Data
finance.yahoo.com - December 5 at 5:27 PM
finance.yahoo.com logoPfizer’s Weight-Loss Pill Disappointment Is an Opening for Biotech Rivals
finance.yahoo.com - December 5 at 5:27 PM
MarketBeat logoNovo Nordisk A/S (NYSE:NVO) Price Target Increased to $115.00 by Analysts at TD Cowen
americanbankingnews.com - December 5 at 3:52 AM
finance.yahoo.com logoNovo Nordisk seeks to use obesity drug findings to prevent weight gain
finance.yahoo.com - December 5 at 2:26 AM
MarketBeat logoNovo Nordisk A/S (NYSE:NVO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
americanbankingnews.com - December 5 at 1:30 AM
marketbeat.com logoNovo Nordisk A/S (NYSE:NVO) Given Consensus Rating of "Moderate Buy" by Brokerages
marketbeat.com - December 5 at 1:28 AM
markets.businessinsider.com logoStrong Buy Recommendation for Novo Nordisk on Robust Growth and Market-Beating Potential
markets.businessinsider.com - December 4 at 8:17 PM
finance.yahoo.com logo8 Forces That Shaped 2023—in Charts
finance.yahoo.com - December 4 at 8:17 PM
cnbc.com logoKeep buying this GLP-1 juggernaut that's already up nearly 50% this year, TD Cowen says
cnbc.com - December 4 at 3:17 PM
marketbeat.com logoNovo Nordisk A/S (NYSE:NVO) Given New $115.00 Price Target at TD Cowen
marketbeat.com - December 4 at 1:27 PM
marketbeat.com logoOzempic vs. Mounjaro:: Battle of the bulge
marketbeat.com - December 4 at 10:15 AM
MarketBeat logoNovo Nordisk A/S (NYSE:NVO) Coverage Initiated at Cantor Fitzgerald
americanbankingnews.com - December 3 at 2:42 AM
finance.yahoo.com logoIs Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
finance.yahoo.com - December 2 at 9:42 AM
msn.com logoAdvocacy for Wegovy: Denmark Signals Cost-Sharing Talks While Novo Spent Millions On Medical Community For Drug Promotion
msn.com - December 1 at 6:10 PM
msn.com logoNovo Nordisk takes legal action against pharmacies selling drugs claiming to contain semgaglutide
msn.com - December 1 at 1:09 PM
msn.com logoWeight Loss Drugs - Novo Nordisk A Primary Beneficiary In Obesity Space Currently Controlled By Two Players, Says Analyst
msn.com - December 1 at 1:09 PM
msn.com logoWill Novo Nordisk Be a Trillion-Dollar Stock by 2030?
msn.com - December 1 at 1:09 PM
marketbeat.com logoNovo Nordisk A/S (NYSE:NVO) Now Covered by Cantor Fitzgerald
marketbeat.com - December 1 at 8:44 AM
finance.yahoo.com logoNovo Nordisk A/S: Raising target to $115
finance.yahoo.com - December 1 at 8:09 AM
finance.yahoo.com logoUPDATE 2-EU watchdog seeks more data from GLP-1 drugmakers on suicidal thoughts
finance.yahoo.com - December 1 at 8:09 AM
msn.com logoNovo Nordisk Claims Ozempic Knockoffs Aren’t Just Cheap — They’re Dangerous
msn.com - November 30 at 8:14 PM
msn.com logoNovo Nordisk Sues Two Florida Pharmacies For Allegedly Selling Impure Weight-Loss Drugs
msn.com - November 30 at 3:13 PM
benzinga.com logoNovo Nordisk Sues Florida Compounding Pharmacies Over Impurities In Products Claiming To Contain Wegovy Ingredient
benzinga.com - November 30 at 3:13 PM
finance.yahoo.com logoUPDATE 1-Novo Nordisk finds compounded Wegovy up to 33% impure, sues Florida pharmacies
finance.yahoo.com - November 30 at 10:12 AM
finance.yahoo.com logoNovo Nordisk finds compounded Wegovy up to 33% impure, sues Florida pharmacies
finance.yahoo.com - November 30 at 10:12 AM
finance.yahoo.com logoIs Alpine Immune Sciences (ALPN) Outperforming Other Medical Stocks This Year?
finance.yahoo.com - November 29 at 12:56 PM
marketbeat.com logoWatch the buy range for Li Auto, MongoDB, Novo Nordisk (NVO)
marketbeat.com - November 29 at 6:10 AM
finance.yahoo.com logoUPDATE 1-Suspected fake Ozempic causes hypoglycemia in 11 in Lebanon
finance.yahoo.com - November 28 at 8:49 PM
finance.yahoo.com logoLilly's Weight-Loss Drug Wallops Novo's In Head-To-Head Study; Novo Stock Dives
finance.yahoo.com - November 28 at 10:48 AM
msn.com logoNovo Nordisk - ADR (NVO) Price Target Increased by 6.24% to 107.60
msn.com - November 27 at 5:58 PM
msn.com logoNovo Nordisk's Flexible Pricing Approach: Push for Broader Access, Innovative Payments
msn.com - November 27 at 12:57 PM
finance.yahoo.com logoGeorge Soros and Jim Cramer Love These Stocks
finance.yahoo.com - November 27 at 12:57 PM
marketbeat.com logoBellRing Brands gets pumped on the Ozempic weight-loss trend (NVO)
marketbeat.com - November 27 at 10:55 AM
seekingalpha.com logoNovo Nordisk: Plenty More Room To Run Despite Its Hefty Valuation
seekingalpha.com - November 27 at 9:30 AM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce
finance.yahoo.com - November 27 at 7:57 AM
finance.yahoo.com logoIs Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?
finance.yahoo.com - November 26 at 2:33 PM
finance.yahoo.com logoCould Ozempic Harm These 3 Medical Device Stocks?
finance.yahoo.com - November 25 at 8:15 AM
benzinga.com logoSpotlight on Novo Nordisk: Analyzing the Surge in Options Activity
benzinga.com - November 24 at 2:15 PM
seekingalpha.com logoNovo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation
seekingalpha.com - November 24 at 10:32 AM
msn.com logoNovo Nordisk invests $2.3 billion in France to boost obesity drug production
msn.com - November 23 at 1:18 PM
barrons.com logoNovo Nordisk Spends Big In France To Expand Obesity Drug Capacity
barrons.com - November 23 at 1:18 PM
finance.yahoo.com logoCORRECTED-UPDATE 2-Novo Nordisk invests $2.3 bln in France to boost obesity drug production
finance.yahoo.com - November 23 at 8:17 AM
Get Novo Nordisk A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.



NVO Media Mentions By Week

NVO Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NVO
News Sentiment
▼
0.36

0.51
▲
Average
Medical
News Sentiment

NVO News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NVO Articles
This Week
▼
22

16
▲
NVO Articles
Average Week

Get Novo Nordisk A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NYSE:NVO) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -